Agreement builds on landmark licensing deal between ARS Pharma and ALK-Abelló A/S, which provided ARS Pharma with $145 million upfront and ALK with commercialization rights to neffy in Canada, United Kingdom, European Union and certain other countries outside the United States New partnership expands ARS Pharma’s direct promotional efforts to nearly 20,000 healthcare providers, reaching key pediatricians ahead of the back-to-school season SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. ...

Group 1 - The investing style described is termed "Fundamental Options," which combines fundamental analysis with options strategies [1] - The investment strategies include income-oriented investments, particularly in Business Development Companies (BDCs) and Utilities, as well as growth investments in technology at reasonable prices [1] - The approach also encompasses deep value investing based on discounted cash flow and other industry-specific valuation methods, along with a focus on Dividend Aristocrats [1] Group 2 - The investor typically engages in long-term stock investments but also employs 20-25 options strategies for various purposes, including hedging, bullish substitutes, neutral trades, trading volatility, and earnings-related trades [1] - Teaching and coaching in various life areas, including investing, is a passion, with a history of authoring a free local investing newsletter [1]

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.The share price of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY ) was buoyant in early trading today after the company released its Q4 and full-year 2024 earnings. At the time o ...

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q4 2024 Earnings Conference Call March 20, 2025 8:30 AM ET Company Participants Justin Chakma - Chief Business Officer Richard Lowenthal - Co-Founder, President and CEO Eric Karas - Chief Commercial Office Kathleen Scott - CFO Conference Call Participants Ryan Deschner - Raymond James Alexa Deemer - Cantor Fitzgerald Louise Chen - Scotia Bank Roanna Ruiz - Leerink Partners Lachlan Hanbury-Brown - William Blair Julian Harrison - BTIG Justin Chakma - Chief Business Offi ...

This quarterly report represents an earnings surprise of 1,400%. A quarter ago, it was expected that this company would post a loss of $0.18 per share when it actually produced a loss of $0.20, delivering a surprise of -11.11%. ARS Pharmaceuticals, Inc. (SPRY) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to loss of $0.07 per share a year ago. These figures are adjusted for non-recurring items. Empirical research shows a ...

ARS Pharmaceuticals (SPRY) Q4 2024 Earnings Call March 20, 2025 08:30 AM ET Company Participants Justin Chakma - Chief Business Officer & SecretaryRichard Lowenthal - Founder, President, CEO & DirectorEric Karas - Chief Commercial OfficerKathleen Scott - Chief Financial OfficerRyan Deschner - Vice President - Equity ResearchAlexa Deemer - Biotechnology Equity Research AssociateLouise Chen - Managing DirectorJulian Harrison - Managing Director Conference Call Participants Roanna Ruiz - Senior Managing Direct ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39756 ARS Pharmaceuticals, Inc. (Exact name of Registrant as specified in its Charter) Delaware 81-1489190 (State or other jurisdicti ...

Financial Performance - Preliminary nef y® net product revenue for Q4 2024 was approximately $6.5 million, with total net product sales for 2024 of approximately $7.1 million since launch[5]. - Cash, cash equivalents, and short-term investments were approximately $314.0 million as of December 31, 2024, expected to support operations for at least three years[5]. - The company aims to achieve a long-term total gross-to-net revenue target of 50% through consistent contracting[9]. Product Delivery and Usage - Over 14,500 nef y two-pack units were delivered in Q4 2024, including more than 1,500 units in the last week of the year[5]. - More than 3,000 healthcare providers have prescribed nef y to date, with 80% in the highest decile for prescribing epinephrine[5]. - More than 1,750 healthcare providers have participated in the nef y Experience Program to date[5]. Market Strategy and Coverage - The company is on track for over 60% commercial insurance coverage by the end of Q1 2025 and over 80% by the end of Q3 2025[9]. - A branded direct-to-consumer marketing campaign for nef y is set to launch in May 2025, aimed at increasing brand recognition[9]. Regulatory and Conference Participation - The sNDA for nef y 1 mg for children weighing 15 to 30 kg has a PDUFA target action date of March 6, 2025, with expected product availability in Q2 2025[9]. - The company will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025[1].

$7.3 million in total neffy® (epinephrine nasal spray) U.S. net product revenue in 2024 since launch in late September 2024 neffy 1 mg approved by U.S. FDA for children aged four and older and weighing 15 kilograms to < 30 kilograms (33 lbs. to < 66 lbs.), expanding the reach of neffy to approximately 2 million younger, school-aged children at risk of a severe allergic reaction $314.0 million in cash, cash equivalents, and short-term investments at year-end 2024, supporting an increased investment in commer ...

neffy 1 mg is the first and only needle-free epinephrine treatment approved for younger children SAN DIEGO, March 05, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, announced today that the U.S. Food and Drug Administration (FDA) has approved neffy® 1 mg (epinephrine nasal spray) for the treatment of Type I Allergic Reacti ...